Browsing by Author "González Aramundiz, José Vicente"
Now showing 1 - 12 of 12
Results Per Page
Sort Options
- ItemDesign of chitosan nanocapsules with compritol 888 ATO (R) for imiquimod transdermal administration. Evaluation of their skin absorption by raman microscopy(2020) Alvarez Figueroa, María Javiera; Narvaez Araya, D.; Armijo Escalona, Nicolás Andrés; Carrasco Flores, E. A.; González Aramundiz, José Vicente
- ItemDifferent Safety Pattern of an Inactivated SARS-CoV-2 Vaccine (CoronaVac®) According to Age Group in a Pediatric Population from 3 to 17 Years Old, in an Open-Label Study in Chile(2023) Le Corre, Nicole; Abarca Villaseca, Katia; Astudillo, Patricio André; Potin Santander, Marcela Patricia; López, Sofía; Goldsack, Macarena; Valenzuela Guerrero, Vania; Schilling Redlich, Andrea; Gaete, Victoria; Rubio, Lilian; Calvo, Mario; Twele, Loreto; González, Marcela; Fuentes, Daniela; Gutiérrez Muñoz, Valentina José; Reyes Zaldivar, Felipe Tomás; Tapia, Lorena I.; Villena, Rodolfo; Retamal Díaz, Angello; Cárdenas, Antonio; Alarcón Bustamante, Eduardo; Xin, Qianqian; González Aramundiz, José Vicente; Álvarez Figueroa, María Javiera; González Muñoz, Pablo Alberto; Bueno Ramírez, Susan; Soto Ramírez, Jorge Andrés; Perret Pérez, Cecilia; Meng, Xing; Kalergis Parra, Alexis MikesDuring the COVID-19 pandemic, the importance of vaccinating children against SARS-CoV-2 was rapidly established. This study describes the safety of CoronaVac® in children and adolescents between 3- and 17-years-old in a multicenter study in Chile with two vaccine doses in a 4-week interval. For all participants, immediate adverse events (AEs), serious AEs (SAEs), and AEs of special interest (AESIs) were registered throughout the study. In the safety subgroup, AEs were recorded 28 days after each dose. COVID-19 surveillance was performed throughout the study. A total of 1139 individuals received the first and 1102 the second dose of CoronaVac®; 835 were in the safety subgroup. The first dose showed the highest number of AEs: up to 22.2% of participants reported any local and 17.1% systemic AE. AEs were more frequent in adolescents after the first dose, were transient, and mainly mild. Pain at the inoculation site was the most frequent AE for all ages. Fever was the most frequent systemic AE for 3–5 years old and headache in 6–17 years old. No SAEs or AESIs related to vaccination occurred. Most of the COVID-19 cases were mild and managed as outpatients. CoronaVac® was safe and well tolerated in children and adolescents, with different safety patterns according to age.
- ItemDifferential immune response induced by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial(2022) Galvez Arriagada, Nicolás Marcelo Salvador; Pacheco Ruidiaz, Gaspar Andrés; Schültz Lombardic, Barbara Melinka; Melo González, Felipe Andrés; Soto Ramírez, Jorge Andrés; Duarte Peñaloza, Luisa Fernanda; González Carreño, Liliana Andrea; Rivera Pérez, Daniela Belén; Ríos Raggio, Mariana; Berríos, Roslye V.; Vazquéz Hernandéz, Yaneisi; Moreno Tapia, Daniela Paz; Vallejos Galvez, Omar Patricio; Andrade Parra, Catalina Andrea; Hoppe Elsholz, Guillermo; Iturriaga, Carolina; Urzua, Marcela; Navarrete, María S.; Rojas González, Álvaro Miguel; Fasce Pineda, Rodrigo Andrés; Fernández, Jorge; Mora, Judith; Ramírez, Eugenio; Gaete Argel, Aracelly; Acevedo Blanco, Mónica Andrea; Valiente Echeverría, Fernando; Soto Rifo, Ricardo; Weiskopf, Daniela; Grifoni, Alba; Sette, Alessandro; Zeng, Gang; Meng, Weining; González Aramundiz, José Vicente; Goldblatt, David; Acuna González, Pablo Ernesto; Abarca Villaseca, Katia; Bueno Ramírez, Susan Marcela; Kalergis Parra, Alexis MikesBackground: The development of vaccines to control the COVID-19 pandemic progression is a worldwide priority. CoronaVac® is an inactivated SARS-CoV-2 vaccine approved for emergency use with robust efficacy and immunogenicity data reported in trials in China, Brazil, Indonesia, Turkey, and Chile. Methods: This study is a randomized, multicenter, and controlled phase 3 trial in healthy Chilean adults aged ≥18 years. Volunteers received two doses of CoronaVac® separated by two (0-14 schedule) or four weeks (0-28 schedule). 2,302 volunteers were enrolled, 440 were part of the immunogenicity arm, and blood samples were obtained at different times. Samples from a single center are reported. Humoral immune responses were evaluated by measuring the neutralizing capacities of circulating antibodies. Cellular immune responses were assessed by ELISPOT and flow cytometry. Correlation matrixes were performed to evaluate correlations in the data measured. Results: Both schedules exhibited robust neutralizing capacities with the response induced by the 0-28 schedule being better. No differences were found in the concentration of antibodies against the virus and different variants of concern between schedules. Stimulation of PBMCs with MPs induced the secretion of IFN-γ and the expression of activation induced markers for both schedules. Correlation matrixes showed strong correlations between neutralizing antibodies and IFN-γ secretion. Conclusions: Immunization with CoronaVac® in Chilean adults promotes robust cellular and humoral immune responses. The 0-28 schedule induced a stronger humoral immune response than the 0-14 schedule.
- ItemLower-Sized Chitosan Nanocapsules for Transcutaneous Antigen Delivery(2018) Bussio, Juan I.; Molina-Perea, Carla; González Aramundiz, José Vicente
- ItemOptimization of physicochemical properties of novel multiple nanoemulsion for complex food matrices through iterative mathematical modelling(2020) Cortés Ríos, Javiera Alejandra; Valdivia-Olivares, R. Y.; Alvarez Figueroa, María Javiera; Rodríguez Fernández, María; González Aramundiz, José Vicente
- ItemPassive and iontophoretic transdermal penetration of chlorpromazine(2008) Alvarez Figueroa, María Javiera; González Aramundiz, José Vicente
- ItemPolymeric nanocapsules for vaccine delivery : influence of the polymeric shell on the interaction with the immune system(2018) Peleteiro, M.; Presas, E.; González Aramundiz, José Vicente; Sanchez Correa, B.; Simon Vazquez, R.; Csaba, N.; Alonso, M.; Gonzalez Fernandez, A.
- ItemProtamine Nanocapsules for the Development of Thermostable Adjuvanted Nanovaccines(2018) González Aramundiz, José Vicente
- ItemProtamine-based nanoparticles as new antigen delivery systems(2015) González Aramundiz, José Vicente; Peleteiro Olmedo, Mercedes; González Fernández, África; Alonso Fernández, María José; Stefánia Csaba, Noemi
- ItemRational design of protamine nanocapsules as antigen delivery carriers(2017) González Aramundiz, José Vicente; Presas, Elena; Dalmau Mena, Inmaculada; Martínez Pulgarín, Susana; Alonso, Covadonga; Escribano, José M.; Alonso, María J.; Csaba, Noemi Stefánia
- ItemSafety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial(2020) Abarca Villaseca, Katia; Rey Jurado, Emma; Muñoz Durango, Natalia; Soto Ramírez, Jorge Andrés; Gálvez Arriagada, Nicolás Marcelo Salvador; Borzutzky Schachter, Arturo; Cerda, Jaime; Villarroel del Pino, Luis A.; González Muñoz, Pablo Alberto; González Aramundiz, José Vicente; Bueno Ramírez, Susan; Kalergis Parra, Alexis Mikes; Valdés-Ferrada, J.; Iturriaga, C.; Urzúa, M.; Madrid, V.; Bueno Ramírez, Susan; Vázquez, Y.
- ItemVersatile protamine nanocapsules to restore miR-145 levels and interfere tumor growth in colorectal cancer cells(2019) Reimondez Troitino, S.; González Aramundiz, José Vicente; Ruiz Banobre, J.; López López, R.; Alonso, M. J.; Csaba, N.; De la Fuente, M.